Here are three things to know.
1. The drug, which is an oseltamivir phosphate capsule, will be sold in strengths of 30 mg, 45 mg and 75 mg.
2. The capsules are approved to treat acute, uncomplicated influenza A and B in patients two-weeks of age and older.
3. Shares of Lupin, which is a drugmaker based in Mumbai, India, closed 0.46 percent up on the BSE stock exchange following the announcement.
More articles on supply chain:
Mylan reaffirms $1B share buyback plan
FDA: IV fluid shortage exacerbated by hurricane damage to Puerto Rico is expected to improve
Stanford Blood Center faces critical shortage of blood, notes the flu is keeping potential donors away
